Rallybio
RLYB · NASDAQ
$16.38+$0.03 (+0.18%)TodayMarket closed ·
Prev close $16.35
EPS: actual vs estimate
Beat the estimate in 7 of the last 8 quarters, by 18.3% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q1 FY26 | -$1.22 | -$1.46 | −20.1% |
| Q4 FY25 | -$1.20 | -$1.03 | +13.9% |
| Q3 FY25 | -$1.75 | -$1.12 | +36.0% |
| Q2 FY25 | -$2.00 | -$1.76 | +12.0% |
| Q1 FY25 | -$2.12 | -$1.68 | +20.8% |
| Q4 FY24 | -$2.34 | -$2.00 | +14.5% |
| Q3 FY24 | -$2.88 | -$2.08 | +27.7% |
| Q2 FY24 | -$3.05 | -$2.96 | +3.0% |
Earnings calls
- Rallybio Corporation, Avenzo Therapeutics, Inc. - M&A Call
- Rallybio Corporation, Candid Therapeutics, Inc. - M&A Call
- Special Call - Rallybio Corporation
- J.P. Morgan 42nd Annual Healthcare Conference 2024
- Special Call - Rallybio Corporation
- Shareholder/Analyst Call - Rallybio Corporation
- 41st Annual J.P. Morgan Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.